VivoSeq
Oncology

Adrenal Cortical Carcinoma

2

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Adrenal Cortical Carcinoma is an early-stage landscape with 2 programs across 2 companies. The most active players are Bristol-Myers Squibb, Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Cabozantinib

Bristol-Myers Squibb

Cemiplimab

Regeneron

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Recruiting·WWest China Hospital·Phase 2·NCT06831175·28 enrolled
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Recruiting·SSun Yat-sen University·Phase 2·NCT06587802·18 enrolled
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
Active, not recruiting·National Cancer Center, Korea·Phase 2·NCT05036434·30 enrolled
A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06900595·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)